Clinical Trial: Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation

U.S., Dec. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07256210) titled 'Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation' on Nov. 20.

Brief Summary: This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic stem cell transplantation in a cohort of pediatric and young adult patients with chemorefractory or minimal residual disease (MRD) positive acute leukemia.

Study Start Date: May 09

Study Type: INTERVENTIONAL

Condition: Acute Myeloid Leukemia A...